✨ HUTCHMED, 췌장암에 대한 2/3상 수루파티닙-캄렐리주맙 콤보 연구의 3상 일부 시작
★ 56 전문 정보 ★
(RTTNews) – HUTCHMED (China) Ltd (HCM, HCM.L,0013.HK), a commercial-stage, biopharmaceutical company, announced on Monday that it has commenced the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib combined with camrelizumab, nab-
🎯 핵심 특징
✅ 고품질
검증된 정보만 제공
⚡ 빠른 업데이트
실시간 최신 정보
💎 상세 분석
전문가 수준 리뷰
📖 상세 정보
(RTTNews) – HUTCHMED (China) Ltd (HCM, HCM.L,0013.HK), a commercial-stage, biopharmaceutical company, announced on Monday that it has commenced the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib combined with camrelizumab, nab-